Abeona Therapeutics (ABEO) 10-K 24 Mar 21 2020 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	001-15771
Entity Registrant Name	ABEONA THERAPEUTICS INC.
Entity Central Index Key	0000318306
Entity Tax Identification Number	83-0221517
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1330 Avenue of the Americas
Entity Address, Address Line Two	33rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	(646)
Local Phone Number	813-4701
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ABEO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 204,160,000
Entity Common Stock, Shares Outstanding		98,788,933
ICFR Auditor Attestation Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 12,596,000	$ 129,258,000
Short-term investments	82,438,000
Prepaid expenses and other current assets	2,708,000	3,132,000
Total current assets	97,742,000	132,390,000
Property and equipment, net	11,322,000	13,157,000
Right-of-use lease assets	7,032,000	8,047,000
Licensed technology, net	1,500,000	36,178,000
Goodwill	32,466,000	32,466,000
Other assets and restricted cash	1,136,000	1,144,000
Total assets	151,198,000	223,382,000
Current liabilities:
Accounts payable	4,695,000	3,763,000
Accrued expenses	3,410,000	5,543,000
Current portion of lease liability	1,713,000	1,699,000
Current portion of loan payable	330,000
Payable to licensor	31,515,000	27,400,000
Deferred revenue	296,000	296,000
Total current liabilities	41,959,000	38,701,000
Loan payable	1,428,000
Long-term lease liabilities	5,260,000	6,251,000
Total liabilities	48,647,000	44,952,000
Commitments and contingencies
Stockholders’ equity:
Common stock - $0.01 par value; authorized 200,000,000 shares;  issued and outstanding 96,131,678 at December 31, 2020;   issued and outstanding 83,622,135 at December 31, 2019;	961,000	836,000
Additional paid-in capital	672,304,000	664,064,000
Accumulated deficit	(570,704,000)	(486,470,000)
Accumulated other comprehensive loss	(10,000)
Total stockholders’ equity	102,551,000	178,430,000
Total liabilities and stockholders’ equity	$ 151,198,000	$ 223,382,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	96,131,678	83,622,135
Common stock, shares outstanding	96,131,678	83,622,135

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 10,000,000
Expenses:
Research and development	30,139,000	48,566,000
General and administrative	23,779,000	20,705,000
Depreciation and amortization	4,586,000	7,819,000
Licensed technology impairment charge	32,916,000
Total expenses	91,420,000	77,090,000
Loss from operations	(81,420,000)	(77,090,000)
Interest and miscellaneous income	1,301,000	1,208,000
Interest and other expense	(4,115,000)	(400,000)
Net loss	$ (84,234,000)	$ (76,282,000)
Basic and diluted loss per common share	$ (0.91)	$ (1.51)
Weighted average number of common shares outstanding – basic and diluted	92,663,574	50,354,596
Other comprehensive loss:
Change in unrealized losses related to  available-for-sale debt securities	$ (10,000)
Comprehensive loss	(84,244,000)	(76,282,000)
License and Other Revenues [Member]
Revenues:
Total revenues	$ 10,000,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 479,000	$ 543,754,000	$ (410,188,000)		$ 134,045,000
Beginning balance, shares at Dec. 31, 2018	47,944,486
Stock option-based compensation expense		7,338,000			7,338,000
Restricted stock-based compensation expense		899,000			899,000
Issuance of common stock and pre-funded warrants  in connection with public offering, net of offering costs	$ 324,000	95,648,000			95,972,000
Issuance of common stock and pre-funded warrants in connection with public offering, net of offering costs, shares	32,382,945
Issuance of common stock under open market sale agreement	$ 31,000	16,930,000			16,961,000
Issuance of common stock under open market sale agreement, shares	3,086,950
Issuance of common stock in connection with the exercise of stock options	$ 3,000	966,000			969,000
Issuance of common stock in connection with the exercise of stock options, shares	303,129
Issuance of common stock in connection  with restricted share awards, net of cancellations	$ 4,000	(4,000)
Issuance of common stock in connection with restricted share awards, net of cancellations, shares	354,625
Shares returned in connection with arbitration  ruling on licensing agreement	$ (5,000)	(1,467,000)			(1,472,000)
Shares returned in connection with arbitration ruling on licensing agreement, shares	(450,000)
Other comprehensive loss
Net loss			(76,282,000)		(76,282,000)
Ending balance, value at Dec. 31, 2019	$ 836,000	664,064,000	(486,470,000)		178,430,000
Ending balance, shares at Dec. 31, 2019	83,622,135
Stock option-based compensation expense		5,853,000			5,853,000
Restricted stock-based compensation expense		2,334,000			2,334,000
Issuance of common stock in connection with the exercise of stock options	$ 1,000	176,000			177,000
Issuance of common stock in connection with the exercise of stock options, shares	77,560
Issuance of common stock in connection  with restricted share awards, net of cancellations	$ 34,000	(34,000)
Issuance of common stock in connection with restricted share awards, net of cancellations, shares	3,414,928
Issuance of common stock in connection with the  exercise of pre-funded warrants	$ 90,000	(89,000)			1,000
Issuance of common stock in connection with the exercise of pre-funded warrants, shares	9,017,055
Other comprehensive loss				(10,000)	(10,000)
Net loss			(84,234,000)		(84,234,000)
Ending balance, value at Dec. 31, 2020	$ 961,000	$ 672,304,000	$ (570,704,000)	$ (10,000)	$ 102,551,000
Ending balance, shares at Dec. 31, 2020	96,131,678

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (84,234,000)	$ (76,282,000)
Adjustments to reconcile net loss to cash used in operating activities:
Non-cash licensed technology impairment charge	32,916,000
Depreciation and amortization	4,586,000	7,819,000
Stock option-based compensation expense	5,853,000	7,338,000
Restricted stock-based compensation expense	2,334,000	899,000
Non-cash interest expense	600,000
Accretion and interest on short-term investments	(70,000)	(266,000)
Accretion of right-of-use lease assets	1,015,000	858,000
Other	347,000	367,000
Change in operating assets and liabilities:
Receivables		81,000
Prepaid expenses and other current assets	424,000	670,000
Other assets	(127,000)	3,000
Accounts payable, accrued expenses and lease liabilities	(2,178,000)	(1,707,000)
Change in payable to licensor	3,515,000	(2,600,000)
Net cash used in operating activities	(35,019,000)	(62,820,000)
Cash flows from investing activities:
Capital expenditures	(1,336,000)	(6,309,000)
Acquisition of licensed technology		(199,000)
Purchases of short-term investments	(170,472,000)
Proceeds from maturities of short-term investments	88,094,000	66,484,000
Net cash (used in)/provided by investing activities	(83,714,000)	59,976,000
Cash flows from financing activities:
Proceeds from loan payable	1,758,000
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of offering costs	1,000	95,972,000
Proceeds from open market sales of common stock		16,961,000
Proceeds from exercise of stock options	177,000	969,000
Net cash provided by financing activities	1,936,000	113,902,000
Net (decrease)/increase in cash, cash equivalents and restricted cash	(116,797,000)	111,058,000
Cash, cash equivalents and restricted cash at beginning of year	130,368,000	19,310,000
Cash, cash equivalents and restricted cash at end of year	13,571,000	130,368,000
Supplemental cash flow information:
Cash and cash equivalents	12,596,000	129,258,000
Restricted cash	975,000	1,110,000
Total cash, cash equivalents and restricted cash	13,571,000	130,368,000
Shares returned in connection with arbitration ruling on licensing agreement		1,472,000
Cash paid for interest
Cash paid for taxes

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Abeona Therapeutics Inc. (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), (ii) ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and next-generation AAV-based gene therapies using the novel AIM™ capsid platform that we have exclusively licensed from the University of North Carolina at Chapel Hill, and internal AAV vector research programs. A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows: Principles of Consolidation The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Uses and Sources of Liquidity The financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued. As of December 31, 2020, we had cash, cash equivalents and short-term investments of $ 95.0 102.6 35.0 We are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance of our future success. Based upon our current operating plans, we believe that we have sufficient resources to fund operations through at least the next 12 months with our existing cash, cash equivalents and short-term investments. We will need to secure additional funding in the future, to carry out all our planned research and development activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient capital resources could have a material adverse effect on our future prospects. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions. Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (“FDIC”). We have not experienced any losses related to amounts in excess of FDIC limits. Short-term Investments Short-term investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (“ASC”) 320, Investments – Debt and Equity Securities Property and Equipment Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three seven five ten Leases We account for leases in accordance with ASC 842, Leases Our leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. Most leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term. Additional information and disclosures required under ASC 842 are included in Note 12. Licensed Technology We have entered into agreements to license the rights to certain technologies. We recorded the purchase price paid for the license, which represents fair value, on our consolidated balance sheet. We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs. Licensed technology is amortized over the life of the patent or the agreement and periodically reviewed for impairment. We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet. We considered the status of our discussions with REGENXBIO in March 2020 as a potential indicator of impairment in accordance with ASC 360-10-35-21. Our impairment test indicated that the carrying value of the license agreement exceeded its fair value and we recorded a $ 32.9 Goodwill As of December 31, 2020 and 2019, goodwill of $ 32.5 Intangibles — Goodwill and Other, Restricted Cash Restricted cash is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows. Segments The Company operates in a single segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. Revenue Recognition We account for contracts with customers in accordance with ASC 606, Revenue from Contracts with Customers Additional information and disclosures required under ASC 606 are included in Note 8. Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, manufacturing, and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired. General and Administrative Expenses General and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses) and investor relations fees. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt. We account for uncertain income tax positions in accordance with ASC 740, Income Taxes Loss Per Common Share We have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying “pre-funded” warrants outstanding during the period. The “pre-funded” warrants were included in the computation of basic net loss per share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the 9,017,055 We do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding stock options, restricted stock and “non-pre-funded” warrants. We did not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods presented: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE For the years ended December 31, 2020 2019 Warrants - 70,000 Restricted stock 2,952,499 354,625 Stock options 5,685,539 6,055,395 Total 8,638,038 6,480,020 Stock-Based Compensation We account for stock-based compensation expense in accordance with ASC 718, Stock Based Compensation The fair value of modifications to share-based awards are determined using Hull White I lattice model which includes assumptions for expected volatility, risk-free interest rate, dividend yield and performance period. If a share-based compensation award is modified after the grant date, incremental compensation expense, if any, is recognized in an amount equal to the excess of the fair value of the modified award over the fair value of the original award immediately before the modification. Incremental compensation expense for vested awards is recognized immediately. For unvested awards, the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original award on the modification date is recognized over the modified service period. The following table summarizes stock option-based option compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 3,126,000 $ 3,932,000 General and administrative 2,727,000 3,406,000 Stock option-based compensation expense included in operating expense 5,853,000 7,338,000 Total stock option-based compensation expense 5,853,000 7,338,000 Tax benefit - - Stock option-based compensation expense, net of tax $ 5,853,000 $ 7,338,000 The following table summarizes restricted stock-based compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 957,000 $ 454,000 General and administrative 1,377,000 445,000 Restricted stock-based compensation expense included in operating expense 2,334,000 899,000 Total restricted stock-based compensation expense 2,334,000 899,000 Tax benefit - - Restricted stock-based compensation expense, net of tax $ 2,334,000 $ 899,000 Additional information and disclosures required under ASC 718 are included in Note 9.

SHORT-TERM INVESTMENTS

SHORT-TERM INVESTMENTS	12 Months Ended
	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
SHORT-TERM INVESTMENTS	NOTE 2 – SHORT-TERM INVESTMENTS The following table summarizes the available-for-sale investments held as of December 31, 2020. There were no SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD Description Fair value U.S. government and agency securities and treasuries $ 82,438,000 The amortized cost of the available-for-sale investments, which is adjusted for amortization of premiums and accretion of discounts to maturity, was $ 82,448,000

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2020 December 31, 2019 Laboratory equipment $ 8,160,000 $ 7,031,000 Furniture and office equipment 1,818,000 1,710,000 Leasehold improvements 8,602,000 8,573,000 Construction work-in-progress 71,000 - 18,651,000 17,314,000 Less: accumulated depreciation and amortization 7,329,000 4,157,000 Property and equipment, net $ 11,322,000 $ 13,157,000 Depreciation and amortization on property and equipment was $ 3.2 2.6

LICENSED TECHNOLOGY

LICENSED TECHNOLOGY	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSED TECHNOLOGY	NOTE 4 – LICENSED TECHNOLOGY On November 4, 2018, we entered into a license agreement with REGENXBIO Inc. (“REGENXBIO”) to obtain rights to an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO’s NAV AAV9 vector for gene therapies for treating MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. Consideration for the rights granted under the original agreement included fees totaling $ 180 million and a running royalty on net sales, including: (i) an initial fee of $ 20 million, $ 10 million of which was due to REGENXBIO shortly after the effective date of the agreement, and $ 10 million of which was to be due on the first anniversary of the effective date of the agreement in November 2019, (ii) annual fees totaling up to $ 100 million, payable in $ 20 million annual installments beginning on the second anniversary of the effective date (the first of which was to remain payable if the agreement were terminated before the second anniversary in November 2020), (iii) sales milestone payments totaling $ 60 million, and (iv) royalties payable in the low double digits to low teens on net sales of products covered under the agreement. The license was being amortized over the life of the patent of eight years 10 million payment due on November 4, 2019 with a $ 3 million payment due on November 4, 2019 and an additional $ 8 million payment (which included $ 1 million of interest) that would have been due no later than April 1, 2020. That $ 8 million payment had been scheduled to be paid by April 1, 2020 and the $ 20 million that had been due to be paid on November 4, 2020 , and both were recorded as payable to licensor on the consolidated balance sheet. The Company has disputed that it is responsible for the $ 8 million and $ 20 million payments, and those payments are the subject of a current arbitration between the Company and REGENXBIO. Prior to the April 1, 2020 deadline, we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we were unable to reach a mutual understanding that we believed would have been favorable for the Company or our programs, and we did not make the $ 8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent us a written demand for the $ 8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated on May 2, 2020 , when the 15-day period expired. There were no penalties for early termination of the license. On May 25, 2020, we filed an arbitration claim with the American Arbitration Association (“AAA”) alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO’s material breach, we are not responsible for payments totaling $ 28 million (which would otherwise have been due in 2020) plus accrued interest ($ 3.5 million as of December 31, 2020). REGENXBIO disputes our arbitration claim and has filed a counterclaim seeking payment of the $ 28 million plus interest, which REGENXBIO argues remains due. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. The tribunal has not yet issued its opinion, and based on the post-hearing schedule an opinion is expected in late second quarter 2021 or early third quarter 2021. Additional information is included in Note 12. We considered the status of our discussions with REGENXBIO in March 2020 as a potential indicator of impairment in accordance with ASC 360-10-35-21. Our impairment test indicated that the carrying value of the license agreement exceeded its fair value and we recorded a $ 32.9 On May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 Licensed technology consists of the following: SCHEDULE OF LICENSED TECHNOLOGY December 31, 2020 December 31, 2019 Licensed technology $ 2,156,000 $ 42,606,000 Less accumulated amortization 656,000 6,428,000 Licensed technology, net $ 1,500,000 $ 36,178,000 The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2020 is as follows: SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS Dec 31, 2020 2021 $ 117,000 2022 117,000 2023 117,000 2024 117,000 2025 117,000 Thereafter 915,000 Total $ 1,500,000 Amortization on licensed technology was $ 1.4 5.2

LOAN PAYABLE

LOAN PAYABLE	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
LOAN PAYABLE	NOTE 5 – LOAN PAYABLE On May 2, 2020, we received loan proceeds in the amount of approximately $ 1.8 1%

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 6 - FAIR VALUE MEASUREMENTS We calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of prepaid expenses and other current assets, other assets, accounts payable, accrued expenses, loan payable, payable to licensor and deferred revenue approximate their carrying amounts due to the relatively short maturity of these instruments. U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2020 and 2019 are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS Description December 31, 2020 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ 82,438,000 $ - $ 82,438,000 $ - $ - Non-recurring Assets: Licensed technology, net $ 1,500,000 $ - $ - $ 1,500,000 $ (32,916,000 ) Goodwill 32,466,000 - - 32,466,000 - Description December 31, 2019 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ - $ - $ - $ - $ - Non-recurring Assets: Licensed technology, net $ 36,178,000 $ - $ - $ 36,178,000 $ (367,000 ) Goodwill 32,466,000 - - 32,466,000 -

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7 – STOCKHOLDERS’ EQUITY 2019 Public Offering of Common Stock and “Pre-Funded” Warrants On December 24, 2019, we closed an underwritten public offering of 32,382,945 2.50 9,017,055 2.4999 0.0001 103.5 In October 2020, all of the 9,017,055 9,017,055 “Non-Pre-Funded” Warrants “Non-pre-funded” warrants to purchase a total of 70,000 expired unexercised during 2020

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	NOTE 8 – REVENUE FROM CONTRACTS WITH CUSTOMERS Sublicense and Inventory Purchase Agreements Relating to CLN1 Disease: The transaction price of the contract includes (i) $ 7.0 26.0 30.0 7.0 Under this arrangement, we recognized $ 7.0 Sublicense Agreement Relating to Rett Syndrome: We assessed the nature of the promised license to determine whether the license has significant stand-alone functionality and evaluated whether such functionality can be retained without ongoing activities by us and determined that the license has significant stand-alone functionality. Furthermore, we have no ongoing activities associated with the license to support or maintain the license’s utility. Based on this, we determined that the pattern of transfer of control of the license to Taysha was at a point in time. The transaction price of the contract includes (i) $ 3.0 26.5 30.0 3.0 Under this arrangement, we recognized $ 3.0

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 – STOCK-BASED COMPENSATION We have two stock-based compensation plans as follows: (1) Abeona Therapeutics Inc. 2015 Equity Incentive Plan, which was approved by stockholders on May 7, 2015 and last amended on May 20, 2020 and (2) Abeona Therapeutics Inc. 2005 Equity Incentive Plan, which no further grants can be made under this plan. Stock Option Repricing Program: 1.16 17.30 1.15 79 0.6 0.3 0.3 2.6 On November 17, 2020, the Compensation Committee unanimously approved the repricing of all stock options outstanding under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan and the Abeona Therapeutics Inc. 2005 Equity Incentive Plan held by the four current members of the Board that had an exercise price per share between $ 1.29 18.50 1.28 four 0.5 0.4 0.1 2.4 2015 Equity Incentive Plan Under our 2015 Equity Incentive Plan, as amended, up to 18,000,000 10 Stock Options: ● Expected volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period which coincides with the expected term, defined below. We believe using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility. ● Expected term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin No. 107, “Share-Based Payment.” ● Risk-free interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant. ● Dividends – we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare a dividend. We used the following weighted-average assumptions to estimate the grant date fair value of the stock options granted for the years indicated: SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED For the years ended December 31, 2020 2019 Expected volatility 110 % 108 % Expected term 6.2 5.1 Risk-free interest rate 0.30 % 2.21 % Expected dividend yield 0.00 % 0.00 % We account for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Summarized stock option information for the 2015 Equity Incentive Plan is as follows: SCHEDULE OF OPTIONS ACTIVITY Options Weighted- Outstanding options at January 1, 2019 5,525,405 $ 8.08 Granted, fair value of $ 5.14 1,490,490 $ 6.53 Exercised (303,129 ) 3.20 Expired/forfeited (917,371 ) 7.95 Outstanding options at December 31, 2019 5,795,395 $ 7.96 Outstanding options at January 01, 2020 5,795,395 7.96 Granted, fair value of $ 1.88 2,645,146 $ 2.26 Exercised (77,560 ) 2.28 Expired/forfeited (2,802,242 ) 6.52 Outstanding options at December 31, 2020 5,560,739 $ 2.21 Non-vested options at December 31, 2019 2,342,706 $ 8.78 Non-vested options at December 31, 2020 2,507,203 $ 1.29 The weighted-average exercise price of stock options granted during the year ended December 31, 2020 was $ 1.42 The intrinsic value related to the outstanding options under this plan was $ 1.7 0.7 0.7 0.6 The total intrinsic value of the options exercised was $ 0 0.4 Further information regarding options outstanding under the 2015 Equity Incentive Plan as of December 31, 2020 is summarized below: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Weighted-average Weighted-average Range of exercise prices Number of options outstanding Remaining life in years Exercise price Number of options exercisable Remaining life in years Exercise price $ 1.02 $ 1.28 4,562,630 7.8 $ 1.20 2,077,915 6.3 $ 1.23 2.31 2.59 161,642 1.4 2.31 161,642 1.4 2.31 4.38 4.78 357,925 3.2 4.43 357,925 3.2 4.43 6.59 7.42 298,865 2.6 7.33 298,865 2.6 7.33 8.54 13.65 66,567 6.5 13.26 47,817 6.3 13.10 14.45 16.02 113,110 1.1 15.96 109,372 1.0 15.96 5,560,739 3,053,536 As of December 31, 2020, the total compensation cost related to non-vested options not recognized is $ 7.8 2.3 Restricted Common Stock SUMMARY OF RESTRICTED STOCK ACTIVITY Restricted Weighted- Outstanding awards at January 1, 2019 - $ - Granted 376,625 $ 3.14 Vested - - Forfeited (22,000 ) 3.14 Outstanding awards at December 31, 2019 354,625 $ 3.14 Outstanding awards at January 01, 2020 354,625 3.14 Granted 5,290,312 $ 1.75 Vested (817,054 ) 2.26 Forfeited (1,875,384 ) 1.75 Outstanding awards at December 31, 2020 2,952,499 $ 1.78 The fair market value of the restricted common stock awards vested was $ 1.3 0 As of December 31, 2020, the total compensation cost related to restricted common stock not recognized is $ 4.1 1.8 2005 Equity Incentive Plan Under the 2005 Equity Incentive Plan, as amended, shares of our authorized but unissued common stock were reserved for issuance to employees, consultants, or to non-employee members of the Board or to any member of the board of directors (or similar governing authority) of any affiliate of the Company. As of January 20, 2015, no additional shares were available for grant under the 2005 Equity Incentive Plan. A total of 124,800 Summarized information for the 2005 Equity Incentive Plan is as follows: SCHEDULE OF OPTIONS ACTIVITY Options Weighted- Outstanding options at January 1, 2019 316,400 $ 14.15 Expired/forfeited (56,400 ) 19.75 Outstanding options at December 31, 2019 260,000 $ 12.94 Outstanding options at January 01, 2020 260,000 12.94 Expired/forfeited (135,200 ) 6.80 Outstanding options at December 31, 2020 124,800 $ 8.55 The intrinsic value related to the outstanding or exercisable options under this plan was $ 0 Further information regarding options outstanding under the 2005 Equity Incentive Plan as of December 31, 2020 is summarized below: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Weighted-average Weighted-average Range of exercise prices Number of options outstanding Remaining life in years Exercise price Number of options exercisable Remaining life in years Exercise price $ 1.28 $ 1.28 80,000 3.2 $ 1.28 80,000 3.2 $ 1.28 11.50 18.50 42,000 2.4 18.17 42,000 2.4 18.17 30.50 113.50 2,800 0.6 72.00 2,800 0.6 72.00 124,800 124,800

401(k) PLAN

401(k) PLAN	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
401(k) PLAN	NOTE 10 – 401(k) PLAN We have a tax-qualified employee savings and retirement plan (the “401(k) Plan”) covering all our employees in the United States. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit ($ 19,500 19,000 50 0.3 0.4

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES Income tax expense differs from the statutory amounts for each of the following years: SCHEDULE OF INCOME TAX EXPENSE 2020 2019 For the years ended December 31, 2020 2019 Income taxes at U.S. statutory rate $ (17,689,000 ) $ (16,020,000 ) Current year reserve 12,020,000 15,976,000 Expenses not deductible 5,669,000 44,000 Total tax expense $ - $ - Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, 2020 December 31, 2019 Deferred tax assets (liabilities): Net operating loss carryforwards $ 61,062,000 $ 50,802,000 General business credit carryforwards 4,398,000 3,939,000 State credits 2,857,000 2,934,000 Property, equipment and goodwill 8,000 (28,000 ) Stock options 9,551,000 7,960,000 Deferred revenue 62,000 62,000 Intangible assets 312,000 1,625,000 Other 70,000 28,000 Gross deferred tax assets 78,320,000 67,322,000 Valuation allowance (78,320,000 ) (67,322,000 ) Net deferred taxes $ - $ - As of December 31, 2020, we had approximately $ 290.8 4.4 SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS Net operating General business credit 2021 $ 5,378,000 $ 56,000 2022 8,230,000 431,000 2023 5,434,000 362,000 2024 8,711,000 287,000 2025 2,370,000 182,000 Thereafter 97,576,000 3,080,000 $ 127,699,000 $ 4,398,000 As of December 31, 2020, we had approximately $ 163.1 We acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both of these corporations were loss-making entities at the time of acquisition. As a result, the net operating losses related to those acquisitions may be subject to annual limitations as well.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Arbitration Proceeding We are currently engaged in an arbitration proceeding with REGENXBIO regarding the former license agreement between the parties relating to use of the AAV9 capsid in our MPS IIIA, MPS IIIB, CLN1 (which has now been sold to Taysha Gene Therapies, as discussed in Note 8 above), and CLN3 programs. The license terminated on May 2, 2020, and on May 25, 2020, we filed an arbitration claim with the American Arbitration Association (“AAA”) alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO’s material breach, we are not responsible for payments totaling $ 28 million (which would otherwise have been due in 2020) plus accrued interest ($ 3.5 million as of December 31, 2020). REGENXBIO disputes our arbitration claim and has filed a counterclaim seeking payment of these amounts. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. The tribunal has not yet issued its opinion, and based on the post-hearing schedule an opinion is expected in late second quarter 2021 or early third quarter 2021. Operating Leases We lease space under operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland, Ohio, as well as administrative offices in New York, New York. We also lease office space in Madrid, Spain as well as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year Components of lease cost under ASC 842 for the years ended December 31, 2020 and 2019 are as follows: SCHEDULE OF COMPONENTS OF LEASE COST 2020 2019 For the years ended December 31, 2020 2019 Operating lease cost $ 1,736,000 $ 1,591,000 Variable lease cost $ 337,000 $ 322,000 Short-term lease cost $ 61,000 $ 133,000 The following table presents information about the amount and timing of cash flows arising from operating leases under ASC 842 as of December 31, 2020: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES Maturity of lease liabilities: 2021 $ 1,713,000 2022 1,727,000 2023 1,741,000 2024 1,781,000 2025 1,799,000 Thereafter 87,000 Total undiscounted operating lease payments 8,848,000 Less: imputed interest 1,875,000 Present value of operating lease liabilities $ 6,973,000 Balance sheet classification: Current portion of lease liability $ 1,713,000 Long-term lease liability 5,260,000 Total operating lease liabilities $ 6,973,000 Other information: Weighted-average remaining lease term for operating leases 61 Weighted-average discount rate for operating leases 9.6 %

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Abeona Therapeutics Inc. (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”), (ii) ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and next-generation AAV-based gene therapies using the novel AIM™ capsid platform that we have exclusively licensed from the University of North Carolina at Chapel Hill, and internal AAV vector research programs. A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of Abeona Therapeutics Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Uses and Sources of Liquidity	Uses and Sources of Liquidity The financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued. As of December 31, 2020, we had cash, cash equivalents and short-term investments of $ 95.0 102.6 35.0 We are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance of our future success. Based upon our current operating plans, we believe that we have sufficient resources to fund operations through at least the next 12 months with our existing cash, cash equivalents and short-term investments. We will need to secure additional funding in the future, to carry out all our planned research and development activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient capital resources could have a material adverse effect on our future prospects.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (“FDIC”). We have not experienced any losses related to amounts in excess of FDIC limits.
Short-term Investments	Short-term Investments Short-term investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (“ASC”) 320, Investments – Debt and Equity Securities
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Depreciation is provided using the straight-line method over estimated useful lives ranging from three seven five ten
Leases	Leases We account for leases in accordance with ASC 842, Leases Our leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. Most leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term. Additional information and disclosures required under ASC 842 are included in Note 12.
Licensed Technology	Licensed Technology We have entered into agreements to license the rights to certain technologies. We recorded the purchase price paid for the license, which represents fair value, on our consolidated balance sheet. We maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs. Licensed technology is amortized over the life of the patent or the agreement and periodically reviewed for impairment. We test our intangible assets for impairment on an annual basis, or more frequently if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug. In connection with each annual impairment assessment and any interim impairment assessment, we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet. We considered the status of our discussions with REGENXBIO in March 2020 as a potential indicator of impairment in accordance with ASC 360-10-35-21. Our impairment test indicated that the carrying value of the license agreement exceeded its fair value and we recorded a $ 32.9
Goodwill	Goodwill As of December 31, 2020 and 2019, goodwill of $ 32.5 Intangibles — Goodwill and Other,
Restricted Cash	Restricted Cash Restricted cash is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows.
Segments	Segments The Company operates in a single segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources.
Revenue Recognition	Revenue Recognition We account for contracts with customers in accordance with ASC 606, Revenue from Contracts with Customers Additional information and disclosures required under ASC 606 are included in Note 8.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical, development cost, clinical trial expense, manufacturing, and consulting. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses primarily consist of personnel, contract personnel, personnel-related expenses to support our administrative and operating activities, facility costs and professional expenses (i.e., legal expenses) and investor relations fees.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets to the extent their realization is in doubt. We account for uncertain income tax positions in accordance with ASC 740, Income Taxes
Loss Per Common Share	Loss Per Common Share We have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying “pre-funded” warrants outstanding during the period. The “pre-funded” warrants were included in the computation of basic net loss per share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the 9,017,055 We do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding stock options, restricted stock and “non-pre-funded” warrants. We did not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods presented: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE For the years ended December 31, 2020 2019 Warrants - 70,000 Restricted stock 2,952,499 354,625 Stock options 5,685,539 6,055,395 Total 8,638,038 6,480,020
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation expense in accordance with ASC 718, Stock Based Compensation The fair value of modifications to share-based awards are determined using Hull White I lattice model which includes assumptions for expected volatility, risk-free interest rate, dividend yield and performance period. If a share-based compensation award is modified after the grant date, incremental compensation expense, if any, is recognized in an amount equal to the excess of the fair value of the modified award over the fair value of the original award immediately before the modification. Incremental compensation expense for vested awards is recognized immediately. For unvested awards, the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original award on the modification date is recognized over the modified service period. The following table summarizes stock option-based option compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 3,126,000 $ 3,932,000 General and administrative 2,727,000 3,406,000 Stock option-based compensation expense included in operating expense 5,853,000 7,338,000 Total stock option-based compensation expense 5,853,000 7,338,000 Tax benefit - - Stock option-based compensation expense, net of tax $ 5,853,000 $ 7,338,000 The following table summarizes restricted stock-based compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 957,000 $ 454,000 General and administrative 1,377,000 445,000 Restricted stock-based compensation expense included in operating expense 2,334,000 899,000 Total restricted stock-based compensation expense 2,334,000 899,000 Tax benefit - - Restricted stock-based compensation expense, net of tax $ 2,334,000 $ 899,000 Additional information and disclosures required under ASC 718 are included in Note 9.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	We do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Potential dilutive securities result from outstanding stock options, restricted stock and “non-pre-funded” warrants. We did not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods presented: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE For the years ended December 31, 2020 2019 Warrants - 70,000 Restricted stock 2,952,499 354,625 Stock options 5,685,539 6,055,395 Total 8,638,038 6,480,020
SCHEDULE OF STOCK BASED COMPENSATION	The following table summarizes stock option-based option compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 3,126,000 $ 3,932,000 General and administrative 2,727,000 3,406,000 Stock option-based compensation expense included in operating expense 5,853,000 7,338,000 Total stock option-based compensation expense 5,853,000 7,338,000 Tax benefit - - Stock option-based compensation expense, net of tax $ 5,853,000 $ 7,338,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF STOCK BASED COMPENSATION	The following table summarizes restricted stock-based compensation for 2020 and 2019, which was allocated as follows: SCHEDULE OF STOCK BASED COMPENSATION For the years ended December 31, 2020 2019 Research and development $ 957,000 $ 454,000 General and administrative 1,377,000 445,000 Restricted stock-based compensation expense included in operating expense 2,334,000 899,000 Total restricted stock-based compensation expense 2,334,000 899,000 Tax benefit - - Restricted stock-based compensation expense, net of tax $ 2,334,000 $ 899,000

SHORT-TERM INVESTMENTS (Tables)

SHORT-TERM INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD	The following table summarizes the available-for-sale investments held as of December 31, 2020. There were no SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD Description Fair value U.S. government and agency securities and treasuries $ 82,438,000

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2020 December 31, 2019 Laboratory equipment $ 8,160,000 $ 7,031,000 Furniture and office equipment 1,818,000 1,710,000 Leasehold improvements 8,602,000 8,573,000 Construction work-in-progress 71,000 - 18,651,000 17,314,000 Less: accumulated depreciation and amortization 7,329,000 4,157,000 Property and equipment, net $ 11,322,000 $ 13,157,000

LICENSED TECHNOLOGY (Tables)

LICENSED TECHNOLOGY (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF LICENSED TECHNOLOGY	Licensed technology consists of the following: SCHEDULE OF LICENSED TECHNOLOGY December 31, 2020 December 31, 2019 Licensed technology $ 2,156,000 $ 42,606,000 Less accumulated amortization 656,000 6,428,000 Licensed technology, net $ 1,500,000 $ 36,178,000
SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS	The aggregate estimated amortization expense for intangible assets remaining as of December 31, 2020 is as follows: SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS Dec 31, 2020 2021 $ 117,000 2022 117,000 2023 117,000 2024 117,000 2025 117,000 Thereafter 915,000 Total $ 1,500,000

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS	Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2020 and 2019 are summarized below: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS Description December 31, 2020 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ 82,438,000 $ - $ 82,438,000 $ - $ - Non-recurring Assets: Licensed technology, net $ 1,500,000 $ - $ - $ 1,500,000 $ (32,916,000 ) Goodwill 32,466,000 - - 32,466,000 - Description December 31, 2019 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ - $ - $ - $ - $ - Non-recurring Assets: Licensed technology, net $ 36,178,000 $ - $ - $ 36,178,000 $ (367,000 ) Goodwill 32,466,000 - - 32,466,000 -

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED	We used the following weighted-average assumptions to estimate the grant date fair value of the stock options granted for the years indicated: SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED For the years ended December 31, 2020 2019 Expected volatility 110 % 108 % Expected term 6.2 5.1 Risk-free interest rate 0.30 % 2.21 % Expected dividend yield 0.00 % 0.00 %
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTIONS ACTIVITY	Summarized stock option information for the 2015 Equity Incentive Plan is as follows: SCHEDULE OF OPTIONS ACTIVITY Options Weighted- Outstanding options at January 1, 2019 5,525,405 $ 8.08 Granted, fair value of $ 5.14 1,490,490 $ 6.53 Exercised (303,129 ) 3.20 Expired/forfeited (917,371 ) 7.95 Outstanding options at December 31, 2019 5,795,395 $ 7.96 Outstanding options at January 01, 2020 5,795,395 7.96 Granted, fair value of $ 1.88 2,645,146 $ 2.26 Exercised (77,560 ) 2.28 Expired/forfeited (2,802,242 ) 6.52 Outstanding options at December 31, 2020 5,560,739 $ 2.21 Non-vested options at December 31, 2019 2,342,706 $ 8.78 Non-vested options at December 31, 2020 2,507,203 $ 1.29
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	Further information regarding options outstanding under the 2015 Equity Incentive Plan as of December 31, 2020 is summarized below: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Weighted-average Weighted-average Range of exercise prices Number of options outstanding Remaining life in years Exercise price Number of options exercisable Remaining life in years Exercise price $ 1.02 $ 1.28 4,562,630 7.8 $ 1.20 2,077,915 6.3 $ 1.23 2.31 2.59 161,642 1.4 2.31 161,642 1.4 2.31 4.38 4.78 357,925 3.2 4.43 357,925 3.2 4.43 6.59 7.42 298,865 2.6 7.33 298,865 2.6 7.33 8.54 13.65 66,567 6.5 13.26 47,817 6.3 13.10 14.45 16.02 113,110 1.1 15.96 109,372 1.0 15.96 5,560,739 3,053,536
SUMMARY OF RESTRICTED STOCK ACTIVITY	Restricted Common Stock SUMMARY OF RESTRICTED STOCK ACTIVITY Restricted Weighted- Outstanding awards at January 1, 2019 - $ - Granted 376,625 $ 3.14 Vested - - Forfeited (22,000 ) 3.14 Outstanding awards at December 31, 2019 354,625 $ 3.14 Outstanding awards at January 01, 2020 354,625 3.14 Granted 5,290,312 $ 1.75 Vested (817,054 ) 2.26 Forfeited (1,875,384 ) 1.75 Outstanding awards at December 31, 2020 2,952,499 $ 1.78
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SCHEDULE OF OPTIONS ACTIVITY	Summarized information for the 2005 Equity Incentive Plan is as follows: SCHEDULE OF OPTIONS ACTIVITY Options Weighted- Outstanding options at January 1, 2019 316,400 $ 14.15 Expired/forfeited (56,400 ) 19.75 Outstanding options at December 31, 2019 260,000 $ 12.94 Outstanding options at January 01, 2020 260,000 12.94 Expired/forfeited (135,200 ) 6.80 Outstanding options at December 31, 2020 124,800 $ 8.55
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	Further information regarding options outstanding under the 2005 Equity Incentive Plan as of December 31, 2020 is summarized below: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Weighted-average Weighted-average Range of exercise prices Number of options outstanding Remaining life in years Exercise price Number of options exercisable Remaining life in years Exercise price $ 1.28 $ 1.28 80,000 3.2 $ 1.28 80,000 3.2 $ 1.28 11.50 18.50 42,000 2.4 18.17 42,000 2.4 18.17 30.50 113.50 2,800 0.6 72.00 2,800 0.6 72.00 124,800 124,800

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX EXPENSE	Income tax expense differs from the statutory amounts for each of the following years: SCHEDULE OF INCOME TAX EXPENSE 2020 2019 For the years ended December 31, 2020 2019 Income taxes at U.S. statutory rate $ (17,689,000 ) $ (16,020,000 ) Current year reserve 12,020,000 15,976,000 Expenses not deductible 5,669,000 44,000 Total tax expense $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, 2020 December 31, 2019 Deferred tax assets (liabilities): Net operating loss carryforwards $ 61,062,000 $ 50,802,000 General business credit carryforwards 4,398,000 3,939,000 State credits 2,857,000 2,934,000 Property, equipment and goodwill 8,000 (28,000 ) Stock options 9,551,000 7,960,000 Deferred revenue 62,000 62,000 Intangible assets 312,000 1,625,000 Other 70,000 28,000 Gross deferred tax assets 78,320,000 67,322,000 Valuation allowance (78,320,000 ) (67,322,000 ) Net deferred taxes $ - $ -
SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS	SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS Net operating General business credit 2021 $ 5,378,000 $ 56,000 2022 8,230,000 431,000 2023 5,434,000 362,000 2024 8,711,000 287,000 2025 2,370,000 182,000 Thereafter 97,576,000 3,080,000 $ 127,699,000 $ 4,398,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LEASE COST	Components of lease cost under ASC 842 for the years ended December 31, 2020 and 2019 are as follows: SCHEDULE OF COMPONENTS OF LEASE COST 2020 2019 For the years ended December 31, 2020 2019 Operating lease cost $ 1,736,000 $ 1,591,000 Variable lease cost $ 337,000 $ 322,000 Short-term lease cost $ 61,000 $ 133,000
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES	The following table presents information about the amount and timing of cash flows arising from operating leases under ASC 842 as of December 31, 2020: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES Maturity of lease liabilities: 2021 $ 1,713,000 2022 1,727,000 2023 1,741,000 2024 1,781,000 2025 1,799,000 Thereafter 87,000 Total undiscounted operating lease payments 8,848,000 Less: imputed interest 1,875,000 Present value of operating lease liabilities $ 6,973,000 Balance sheet classification: Current portion of lease liability $ 1,713,000 Long-term lease liability 5,260,000 Total operating lease liabilities $ 6,973,000 Other information: Weighted-average remaining lease term for operating leases 61 Weighted-average discount rate for operating leases 9.6 %

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	8,638,038	6,480,020
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		70,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,952,499	354,625
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,685,539	6,055,395

SCHEDULE OF STOCK BASED COMPENS

SCHEDULE OF STOCK BASED COMPENSATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 5,853,000	$ 7,338,000
Tax benefit
Stock based compensation expense, net of tax	5,853,000	7,338,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	5,853,000	7,338,000
Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	3,126,000	3,932,000
Share-based Payment Arrangement, Option [Member] | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	2,727,000	3,406,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	2,334,000	899,000
Tax benefit
Stock based compensation expense, net of tax	2,334,000	899,000
Restricted stock-based compensation expense included in operating expense	2,334,000	899,000
Restricted Stock [Member] | Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	957,000	454,000
Restricted Stock [Member] | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 1,377,000	$ 445,000

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)Integer	Oct. 31, 2020shares	Dec. 31, 2019USD ($)
Lessor, Lease, Description [Line Items]
Cash, cash equivalents and short-term investments	$ 95,000,000
Net assets	102,600,000
Net cash used in operating activities	35,000,000
Non-cash licensed technology impairment charge	32,900,000
Goodwill	$ 32,466,000		$ 32,466,000
Number of Operating Segments | Integer	1
Pre-Funded Warrants [Member]
Lessor, Lease, Description [Line Items]
Warrants converted to shares | shares		9,017,055
Equipment [Member] | Minimum [Member]
Lessor, Lease, Description [Line Items]
Property and equipment estimated useful lives	3 years
Equipment [Member] | Maximum [Member]
Lessor, Lease, Description [Line Items]
Property and equipment estimated useful lives	7 years
Leasehold Improvements [Member] | Minimum [Member]
Lessor, Lease, Description [Line Items]
Property and equipment estimated useful lives	5 years
Leasehold Improvements [Member] | Maximum [Member]
Lessor, Lease, Description [Line Items]
Property and equipment estimated useful lives	10 years

SCHEDULE OF AVAILABLE-FOR-SALE

SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)	Dec. 31, 2020USD ($)
Investments, Debt and Equity Securities [Abstract]
U.S. government and agency securities and treasuries	$ 82,438,000

SHORT-TERM INVESTMENTS (Details

SHORT-TERM INVESTMENTS (Details Narrative)	Dec. 31, 2020USD ($)
Investments, Debt and Equity Securities [Abstract]
Debt Securities, Available-for-sale, Amortized Cost	$ 82,448,000

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,651,000	$ 17,314,000
Less: accumulated depreciation and amortization	7,329,000	4,157,000
Property and equipment, net	11,322,000	13,157,000
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,160,000	7,031,000
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,818,000	1,710,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,602,000	8,573,000
Construction Work-in-Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 71,000

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 3.2	$ 2.6

SCHEDULE OF LICENSED TECHNOLOGY

SCHEDULE OF LICENSED TECHNOLOGY (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed technology	$ 2,156,000	$ 42,606,000
Less accumulated amortization	656,000	6,428,000
Licensed technology, net	$ 1,500,000	$ 36,178,000

SCHEDULE OF AMORTIZATION EXPENS

SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 117,000
2022	117,000
2023	117,000
2024	117,000
2025	117,000
Thereafter	915,000
Licensed technology, net	$ 1,500,000	$ 36,178,000

LICENSED TECHNOLOGY (Details Na

LICENSED TECHNOLOGY (Details Narrative) - USD ($)	Nov. 04, 2020	Apr. 17, 2020	Apr. 02, 2020	Nov. 04, 2018	May 15, 2015	Dec. 31, 2020	Dec. 31, 2019	Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]
Payments for Royalties	$ 20,000,000		$ 8,000,000
Due to Related Parties, Current						$ 31,515,000	$ 27,400,000
Program Rights Obligations, Current		$ 8,000,000
Interest Payable								$ 1,000,000
Debt Instrument, Maturity Date			Nov. 4, 2020
License termination date		May 2, 2020
Debt Instrument, Periodic Payment, Principal						28,000,000
Debt Instrument, Increase, Accrued Interest						3,500,000
Non-cash licensed technology impairment charge						32,916,000
Amortization of intangible assets						1,400,000	$ 5,200,000
Abeona Therapeutics LLC [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life					20 years
Original License Agreement [Member]
Indefinite-lived Intangible Assets [Line Items]
Program Rights Obligations, Current								10,000,000
Eb Agreement [Member]
Indefinite-lived Intangible Assets [Line Items]
Program Rights Obligations, Current								3,000,000
Eb Agreement [Member] | Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1
Indefinite-lived Intangible Assets [Line Items]
Program Rights Obligations, Current								$ 8,000,000
REGENXBIO [Member]
Indefinite-lived Intangible Assets [Line Items]
Due remains value						28,000,000
Licensing Agreements [Member] | REGENXBIO [Member]
Indefinite-lived Intangible Assets [Line Items]
Royalty Expense				$ 180,000,000
Payments for Royalties	$ 20,000,000			60,000,000
IncomeTax Reconciliation Current Year Reserve				10,000,000
Due to Related Parties, Current				$ 10,000,000
Finite-lived intangible asset, useful life				8 years
Loss Contingency Accrual						8,000,000
Payments for Legal Settlements						$ 20,000,000
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]
Indefinite-lived Intangible Assets [Line Items]
Debt Instrument, Face Amount				$ 100,000,000

LOAN PAYABLE (Details Narrative

LOAN PAYABLE (Details Narrative) - USD ($)	May 02, 2020	Dec. 31, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Proceeds from loan		$ 1,758,000
Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Proceeds from loan	$ 1,800,000
Debt interest rate	1.00%

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Short Term Investment [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	$ 82,438,000
Fair value disclosure of gain loss
Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	82,438,000
Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	1,500,000	36,178,000
Fair value disclosure of gain loss	(32,916,000)	(367,000)
Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	1,500,000	36,178,000
Goodwill [Member] | Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	32,466,000	32,466,000
Fair value disclosure of gain loss
Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets
Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value disclosure of assets	$ 32,466,000	$ 32,466,000

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	Dec. 24, 2019	Oct. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Common Stock [Member]
Class of Warrant or Right [Line Items]
Pre-funded warrants exercised and converted shares		9,017,055
Non-Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase				70,000
Non-Pre-Funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant expiration, description			expired unexercised during 2020
2019 Public Offering [Member]
Class of Warrant or Right [Line Items]
Issuance of common shares	32,382,945
Shares issued, price per share	$ 2.50
Issuance of common shares, value	$ 103.5
2019 Public Offering [Member] | Pre - Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase		9,017,055
Warrants exercise price	$ 0.0001
2019 Public Offering [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase	9,017,055
Warrants exercise price	$ 2.4999

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details Narrative) - USD ($)	Aug. 14, 2020	Oct. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 10,000,000
Sublicense Andnventory Purchase Agreements [Member]
Disaggregation of Revenue [Line Items]
Fixed consideration	$ 7,000,000		7,000,000
Sublicense Andnventory Purchase Agreements [Member] | Event Based Milestone Payments [Member] | Maximum [Member]
Disaggregation of Revenue [Line Items]
Milestone payments	26,000,000
Sublicense Andnventory Purchase Agreements [Member] | Sales Based Milestone Payments [Member] | Maximum [Member]
Disaggregation of Revenue [Line Items]
Milestone payments	$ 30,000,000
Sublicense Andnventory Purchase Agreements [Member] | License [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			7,000,000
Sublicense Agreement [Member]
Disaggregation of Revenue [Line Items]
Fixed consideration		$ 3,000,000	3,000,000
Sublicense Agreement [Member] | Event Based Milestone Payments [Member] | Maximum [Member]
Disaggregation of Revenue [Line Items]
Milestone payments		26,500,000
Sublicense Agreement [Member] | Sales Based Milestone Payments [Member] | Maximum [Member]
Disaggregation of Revenue [Line Items]
Milestone payments		$ 30,000,000
Sublicense Agreement [Member] | License [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 3,000,000

SCHEDULE OF WEIGHTED-AVERAGE AS

SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Expected volatility	110.00%	108.00%
Expected term	6 years 2 months 12 days	5 years 1 month 6 days
Risk-free interest rate	0.30%	2.21%
Expected dividend yield	0.00%	0.00%

SCHEDULE OF OPTIONS ACTIVITY (D

SCHEDULE OF OPTIONS ACTIVITY (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Options, Outstanding options	5,795,395	5,525,405
Beginning balance, Weighted- average exercise price, Outstanding options	$ 7.96	$ 8.08
Options, Granted, fair value	2,645,146	1,490,490
Weighted- average exercise price, Granted, fair value	$ 2.26	$ 6.53
Options, Exercised	(77,560)	(303,129)
Weighted- average exercise price, Exercised	$ 2.28	$ 3.20
Options, Expired/forfeited	(2,802,242)	(917,371)
Weighted- average exercise price, Expired/forfeited	$ 6.52	$ 7.95
Ending balance, Options, Outstanding options	5,560,739	5,795,395
Ending balance, Options, Outstanding options	$ 2.21	$ 7.96
Options, Non-vested options	2,507,203	2,342,706
Weighted- average exercise price, Non-vested options	$ 1.29	$ 8.78
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Options, Outstanding options	260,000	316,400
Beginning balance, Weighted- average exercise price, Outstanding options	$ 12.94	$ 14.15
Options, Expired/forfeited	(135,200)	(56,400)
Weighted- average exercise price, Expired/forfeited	$ 6.80	$ 19.75
Ending balance, Options, Outstanding options	124,800	260,000
Ending balance, Options, Outstanding options	$ 8.55	$ 12.94

SCHEDULE OF OPTIONS ACTIVITY _2

SCHEDULE OF OPTIONS ACTIVITY (Details) (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of granted	$ 1.88	$ 5.14

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	5,560,739	5,795,395	5,525,405
Weighted-average Remaining life in years	10 years
Weighted-average Exercise price	$ 2.21	$ 7.96	$ 8.08
Number of options exercisable	3,053,536
2015 Equity Incentive Plan [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	$ 1.02
Range of exercise price, upper limit	$ 1.28
Number of options outstanding	4,562,630
Weighted-average Remaining life in years	7 years 9 months 18 days
Weighted-average Exercise price	$ 1.20
Number of options exercisable	2,077,915
Weighted-average Remaining life in years, exercisable	6 years 3 months 18 days
Weighted-average Exercise price, exercisable	$ 1.23
2015 Equity Incentive Plan [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	2.31
Range of exercise price, upper limit	$ 2.59
Number of options outstanding	161,642
Weighted-average Remaining life in years	1 year 4 months 24 days
Weighted-average Exercise price	$ 2.31
Number of options exercisable	161,642
Weighted-average Remaining life in years, exercisable	1 year 4 months 24 days
Weighted-average Exercise price, exercisable	$ 2.31
2015 Equity Incentive Plan [Member] | Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	4.38
Range of exercise price, upper limit	$ 4.78
Number of options outstanding	357,925
Weighted-average Remaining life in years	3 years 2 months 12 days
Weighted-average Exercise price	$ 4.43
Number of options exercisable	357,925
Weighted-average Remaining life in years, exercisable	3 years 2 months 12 days
Weighted-average Exercise price, exercisable	$ 4.43
2015 Equity Incentive Plan [Member] | Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	6.59
Range of exercise price, upper limit	$ 7.42
Number of options outstanding	298,865
Weighted-average Remaining life in years	2 years 7 months 6 days
Weighted-average Exercise price	$ 7.33
Number of options exercisable	298,865
Weighted-average Remaining life in years, exercisable	2 years 7 months 6 days
Weighted-average Exercise price, exercisable	$ 7.33
2015 Equity Incentive Plan [Member] | Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	8.54
Range of exercise price, upper limit	$ 13.65
Number of options outstanding	66,567
Weighted-average Remaining life in years	6 years 6 months
Weighted-average Exercise price	$ 13.26
Number of options exercisable	47,817
Weighted-average Remaining life in years, exercisable	6 years 3 months 18 days
Weighted-average Exercise price, exercisable	$ 13.10
2015 Equity Incentive Plan [Member] | Range six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	14.45
Range of exercise price, upper limit	$ 16.02
Number of options outstanding	113,110
Weighted-average Remaining life in years	1 year 1 month 6 days
Weighted-average Exercise price	$ 15.96
Number of options exercisable	109,372
Weighted-average Remaining life in years, exercisable	1 year
Weighted-average Exercise price, exercisable	$ 15.96
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	124,800	260,000	316,400
Weighted-average Exercise price	$ 8.55	$ 12.94	$ 14.15
Number of options exercisable	124,800
2005 Equity Incentive Plan [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	$ 1.28
Range of exercise price, upper limit	$ 1.28
Number of options outstanding	80,000
Weighted-average Remaining life in years	3 years 2 months 12 days
Weighted-average Exercise price	$ 1.28
Number of options exercisable	80,000
Weighted-average Remaining life in years, exercisable	3 years 2 months 12 days
Weighted-average Exercise price, exercisable	$ 1.28
2005 Equity Incentive Plan [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	11.50
Range of exercise price, upper limit	$ 18.50
Number of options outstanding	42,000
Weighted-average Remaining life in years	2 years 4 months 24 days
Weighted-average Exercise price	$ 18.17
Number of options exercisable	42,000
Weighted-average Remaining life in years, exercisable	2 years 4 months 24 days
Weighted-average Exercise price, exercisable	$ 18.17
2005 Equity Incentive Plan [Member] | Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise price, lower limit	30.50
Range of exercise price, upper limit	$ 113.50
Number of options outstanding	2,800
Weighted-average Remaining life in years	7 months 6 days
Weighted-average Exercise price	$ 72
Number of options exercisable	2,800
Weighted-average Remaining life in years, exercisable	7 months 6 days
Weighted-average Exercise price, exercisable	$ 72

SUMMARY OF RESTRICTED STOCK ACT

SUMMARY OF RESTRICTED STOCK ACTIVITY (Details) - 2015 Equity Incentive Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock awards, Vested	(1,300,000)	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ending balance, Restricted common stock awards, Outstanding awards	354,625
Ending balance, Weighted-average grant date fair value, Outstanding awards	$ 3.14
Restricted common stock awards, Granted	5,290,312	376,625
Weighted-average grant date fair value, Granted	$ 1.75	$ 3.14
Restricted common stock awards, Vested	(817,054)
Weighted-average grant date fair value, Vested	$ 2.26
Restricted common stock awards	(1,875,384)	(22,000)
Weighted-average grant date fair value, Forfeited	$ 1.75	$ 3.14
Ending balance, Restricted common stock awards, Outstanding awards	2,952,499	354,625
Ending balance, Weighted-average grant date fair value, Outstanding awards	$ 1.78	$ 3.14

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative)	Nov. 17, 2020USD ($)Grantees$ / shares	Nov. 10, 2020USD ($)Grantees$ / shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018$ / sharesshares
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares			$ 1.42
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares			$ 2.21	$ 7.96	$ 8.08
Common stock authorized but unissued | shares			18,000,000
Maximum contractual term			10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares			$ 2.26	$ 6.53
Intrinsic value outstanding options | $			$ 1,700,000	$ 700,000
Intrinsic value exercisable options | $			700,000	600,000
Total intrinsic value of the options exercised | $			0	$ 400,000
Compensation cost related to non-vested options not recognized | $			$ 7,800,000
Weighted average period total compensation costs related to non-vested options			2 years 3 months 18 days
Shares of restricted common stock vested | shares			1,300,000	0
Compensation cost related to restricted common stock not recognized | $			$ 4,100,000
Weighted average compensation costs related to restricted common stock			1 year 9 months 18 days
Options outstanding and exercisable | shares			5,560,739	5,795,395	5,525,405
2015 Equity Incentive Plan [Member] | Eligible Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares		$ 1.15
Number of grantees affected | Grantees		79
Incremental compensation cost | $		$ 300,000	$ 600,000
Recognized as compensation expense | $			300,000
Incremental compensation costs recognized term		2 years 7 months 6 days
2015 Equity Incentive Plan [Member] | Eligible Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares		$ 1.16
2015 Equity Incentive Plan [Member] | Eligible Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares		$ 17.30
2015 Equity Incentive Plan [Member] | Eligible Director Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares	$ 1.28
Number of grantees affected | Grantees	4
Incremental compensation cost | $	$ 100,000		500,000
Recognized as compensation expense | $			$ 400,000
Incremental compensation costs recognized term	2 years 4 months 24 days
2015 Equity Incentive Plan [Member] | Eligible Director Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares	$ 1.29
2015 Equity Incentive Plan [Member] | Eligible Director Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares	$ 18.50
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per share | $ / shares			$ 8.55	$ 12.94	$ 14.15
Intrinsic value outstanding options | $			$ 0	$ 0
Options outstanding and exercisable | shares			124,800	260,000	316,400

401(k) PLAN (Details Narrative)

401(k) PLAN (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)Integer	Dec. 31, 2019USD ($)
Retirement Benefits [Abstract]
Maximum annual contribution per employee under 401(k) plan	$ 19,500	$ 19,000
Number of investment options | Integer	50
Company contributions under 401 (k) Plan	$ 300,000	$ 400,000

SCHEDULE OF INCOME TAX EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes at U.S. statutory rate	$ (17,689,000)	$ (16,020,000)
Current year reserve	12,020,000	15,976,000
Expenses not deductible	5,669,000	44,000
Total tax expense

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 61,062,000	$ 50,802,000
General business credit carryforwards	4,398,000	3,939,000
State credits	2,857,000	2,934,000
Property, equipment and goodwill	8,000	(28,000)
Stock options	9,551,000	7,960,000
Deferred revenue	62,000	62,000
Intangible assets	312,000	1,625,000
Other	70,000	28,000
Gross deferred tax assets	78,320,000	67,322,000
Valuation allowance	(78,320,000)	(67,322,000)
Net deferred taxes

SUMMARY OF NET OPERATING LOSS A

SUMMARY OF NET OPERATING LOSS AND GENERAL BUSINESS CREDIT CARRYFORWARDS (Details)	Dec. 31, 2020USD ($)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 127,699,000
General business credit carryforwards	4,398,000
Tax Year 2021 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	5,378,000
General business credit carryforwards	56,000
Tax Year 2022 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	8,230,000
General business credit carryforwards	431,000
Tax Year 2023 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	5,434,000
General business credit carryforwards	362,000
Tax Year 2024 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	8,711,000
General business credit carryforwards	287,000
Tax Year Two Thousand Twenty Five [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	2,370,000
General business credit carryforwards	182,000
Thereafter [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	97,576,000
General business credit carryforwards	$ 3,080,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 290,800,000
General business credit carryforwards	4,398,000
Net operating loss carryforwards not expired and carried forward indefinitely, amount	$ 163,100,000

SCHEDULE OF COMPONENTS OF LEASE

SCHEDULE OF COMPONENTS OF LEASE COST (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 1,736,000	$ 1,591,000
Variable lease cost	337,000	322,000
Short-term lease cost	$ 61,000	$ 133,000

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2021	$ 1,713,000
2022	1,727,000
2023	1,741,000
2024	1,781,000
2025	1,799,000
Thereafter	87,000
Total undiscounted operating lease payments	8,848,000
Less: imputed interest	1,875,000
Total operating lease liabilities	6,973,000
Current portion of lease liability	1,713,000	$ 1,699,000
Long-term lease liability	$ 5,260,000	$ 6,251,000
Weighted-average remaining lease term for operating leases	61 months
Weighted-average discount rate for operating leases	9.60%

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Product Liability Contingency [Line Items]
Debt Instrument, Periodic Payment, Principal	$ 28
Debt Instrument, Increase, Accrued Interest	3.5
RDEB Product [Member]
Product Liability Contingency [Line Items]
Debt Instrument, Periodic Payment, Principal	28
Debt Instrument, Increase, Accrued Interest	$ 3.5
Operating lease, term of contract	non-cancelable lease term of less than one year